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How would you manage this small
melanocytic choroidal tumour?
CASE REPORT
A 68-year-old lady was referred to the Jules-Gonin Eye Hospital
(Lausanne, Switzerland), 6 months after her ophthalmologist
had observed, during routine eye examination, an asymptom-
atic, parapapillary, choroidal pigmented tumour in the left eye,
covered with drusen and without any orange pigment or asso-
ciated serous retinal detachment (ﬁgure 1A).
Best corrected Snellen visual acuity was 0.7 in the right eye,
related to a relative hypermetropic amblyopia known since
childhood, and 1.0 in the left eye. On ﬂuorescein angiography,
pigment epithelial alterations were present, with limited diffu-
sion of the dye (ﬁgure 1B).
QUESTIONS
1. What is your diagnosis?
2. How would you manage?
3. What is the prognosis?
For answers see 1539.
Domniki Papadopoulou, Alexandre P Moulin, Leonidas Zografos,
Ann Schalenbourg
Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
Correspondence to Dr Ann Schalenbourg, Jules-Gonin Eye Hospital, 15, Avenue de
France, Lausanne CH-1004, Switzerland; ann.schalenbourg@fa2.ch
Contributors The four authors are justiﬁably credited with authorship according to
the authorship criteria. In detail, DP, AS, LZ: conception, design, analysis and
interpretation of data, drafting of the manuscript, ﬁnal approval given. APM: critical
revision of manuscript analysis and interpretation of data, ﬁnal approval given.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
Published Online First 27 September 2012
Br J Ophthalmol 2012;96:1530. doi:10.1136/bjophthalmol-2012-302329
Figure 1 (A) Panoramic fundus picture (PANORET camera) of a small pigmented parapapillary choroidal tumour covered with drusen and without
orange pigment at its surface. (B) On ﬂuorescein angiography, the absence of an associated serous retinal detachment or leaking ‘pin points’ is
conﬁrmed, as well as the presence of pigment epithelial alterations at the lesion’s periphery.
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ANSWERS
For questions see 1530
1. In order for the work-up of a pigmented choroidal tumour
to be complete, a B-scan ultrasonography must be per-
formed. All the while conﬁrming the ophthalmoscopic
impression that this was an intraocular tumour with a
limited thickness (height (H)=2.5 mm), echography
revealed the surprising presence of a large extrascleral exten-
sion (H=6.0 mm) (ﬁgure 2A). The diagnosis of a presumed
small choroidal melanoma hiding a large extrascleral exten-
sion was made.
2. The usual general check-up for uveal melanoma including a
liver scan did not show distant metastases. In addition, a
high deﬁnition orbital MRI (3 Tesla) with gadolinium injec-
tion was organised, on which the extrascleral extension
appeared to be circumscribed without invasion of the optic
nerve sheath (ﬁgure 2B). Extraocular extensions have been
demonstrated to occur through emissary scleral channels, in
this case a posterior ciliary artery, rather than an erosion of
the sclera.1 As both the ultrasound and MRI images did not
suggest the contrary, a conservative therapeutic approach
including excision of the extraocular extension followed by
proton therapy was proposed, to which the patient agreed.
During tantalum clip surgery, the extrascleral tumour nodule
could be easily isolated from both the intact sclera and the
surrounding orbital tissues, and was subsequently removed
(ﬁgure 2C). Two weeks later, the intraocular tumour was irra-
diated with external proton beam irradiation, delivering 60
Gray in four fractions over four consecutive days,2 with pos-
terior safety margins increased with 3 mm to include the
orbital tissues surrounding the site of the previously excised
extraocular extension in the target volume.
Six months later, the tumour was reduced to a ﬂat scar,
with a thickness of 1.2 mm and no signs of an orbital recur-
rence on B-scan ultrasonography.
3. On histopathological examination, the extrascleral extension
consisted of mixed type (fusiform and epithelioid) uveal
melanoma cells (ﬁgure 2D), with the epithelioid cells dis-
playing prominent nucleoli and a back-to-back loop vascular
pattern. The immunohistochemic proliferation index (Ki67)
was about 5%. These elements have been classically corre-
lated with a poor vital prognosis.
Cytogenetic analysis (array-comparative genomic hybrid-
isation or array-CGH) was also performed, revealing a com-
plete gain of the entire chromosome 20 and a partial
ampliﬁcation and gain of chromosome 6p, but without
monosomy 3 or 8q gains. According to the recent literature,
and assuming that this analysis is also representative of the
intraocular tumour part, such a result is correlated with a
low metastatic risk.3
Figure 2 (A) B-scan ultrasonography reveals the presence of an extrascleral extension, close to the optic nerve and surprisingly large (height
(H)=6.0 mm), compared with the intraocular tumour part (H=2.5 mm). (B) A high deﬁnition (3 Tesla) MRI of the orbit gives the image of a
circumscribed extraocular tumour, without evidence of optic nerve sheath invasion (T1, with gadolinium). (C) Macroscopic image of the excised
encapsulated extraocular extension. (D) Histopathological analysis demonstrates an inﬁltration of the scleral and peri-scleral connective tissue by a
proliferation of epithelioid and fusiform melanoma cells, isolated or organised in large, sometimes conﬂuent nests or sheets (H&E stain; original
magniﬁcation ×126).
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DISCUSSION
This case report illustrates the challenges with regard to the
diagnosis, management and prognosis of a small choroidal mel-
anoma hiding a large extrascleral extension.
The ophthalmoscopic and angiographic characteristics of this
pseudo small pigmented parapapillary tumour were closer to
those of a large nevus (absence of symptoms, orange pigment,
or serous retinal detachment and presence of drusen and
pigment epithelial alterations) than those of a melanocytic
tumour at risk of growth.4 5 Even the thickness of the intraocu-
lar tumour did not exceed 3 mm. However, the presence of an
extrascleral extension on B-scan ultrasonography changed the
diagnosis and subsequent management and prognosis com-
pletely. Choroidal nevi are quite frequent in Caucasians, with
an estimated prevalence between 5% and 8%6 against an
annual incidence of about 5–7/million for choroidal melan-
oma.6 7 Consequently, it might be tempting for the general
ophthalmologist in a busy practice not to refer a patient with a
slightly elevated nevus for B-scan ultrasonography or to defer
it, with the ulterior risk of conservative treatment becoming
difﬁcult or even impossible. Our patient experienced for this
very reason a delay in referral of 6 months.
An extrascleral extension, present in 2%–15% of all uveal
melanomas,1 2 8 9 10 invariably raises the question whether—in
analogy to the dermatologists’ approach of cutaneous
melanoma—orbital exenteration, or at least adjuvant orbital
irradiation, is indicated. With regard to local tumour control, the
presence of an extraocular extension has not been shown to be a
signiﬁcant risk factor for local recurrence after conservative
proton therapy.2 8 10 With regard to survival, the Collaborative
Ocular Melanoma Study (COMS report nr 24) found no survival
advantage attributable to pre-enucleation radiation of the
orbit,11 albeit with only 20 Gray, despite the presence of an
extrascleral extension in 8.2% of all eyes with uveal melanoma
primarily enucleated in the frame of this study.9 A similar study
using an effective 60 Gray irradiating the whole orbit has not
been undertaken yet, researchers probably being discouraged by
the major radiation side effects described for other orbital
tumours without a therapeutic alternative.12
With the introduction of cytogenetic and molecular tests,
uveal melanoma prognostication has become a hot topic in
recent literature and different techniques are being evaluated,
such as FISH, array-CGH, multiplex ligation-dependent probe
ampliﬁcation (MLPA) and gene expression proﬁling. All
researchers agree that the presence of monosomy 3 is the most
important metastatic risk factor. Damato et al even found that
some ‘traditional’, clinical risk factors, such as extraocular
extension, lost signiﬁcance when cytogenetic and histological
data were included in their statistical prognostication model.3
Though these prognostic tests have changed profoundly the
research on uveal melanoma, effective ‘tailored’ adjuvant ther-
apies preventing metastatic disease have yet to be developed.
In conclusion, B-scan ultrasonography belongs to the basic
work-up of small melanocytic tumours. The presence of a large
encapsulated extrascleral extension is not necessarily a contra-
indication for conservative treatment, all the while requiring
enlarged radiation safety margins. Following surgical resection,
the extrascleral tumour part can be used for cytogenetic analysis,
prognostication and deﬁning the terms of oncological follow-up.
However, no effective adjuvant treatment based on speciﬁc
cytogenetic tumour characteristics has been developed yet.
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